Cell and agonist-specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells

Journal of Neurochemistry

Volumn 98, Issue 3, 2006, Pages 812-823

  Crocker, Stephen J ^a   Milner, Richard ^a   Pham Mitchell, Ngan ^a   Campbell, Lain L ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Astrocyte; Cytokine; Lipopolysaccharide; Microglia; Serum

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; DOWN REGULATION; ENCEPHALITIS; FEMALE; GENE CONTROL; GENE FUNCTION; GLIA CELL; MICROGLIA; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TIMED DRUG RELEASE;

ANIMALS; CELLS, CULTURED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; NEUROGLIA; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33745921491     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.03927.x     Document Type: Article

References (64)

1. Ahonen M., Poukkula M., Baker A. H., Kashiwagi M., Nagase H., Eriksson J. E. and Kahari V. M. (2003) Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 22, 2121-2134.
2. Aldskogius H. (2005) Repairing CNS myelin - astrocytes have to do their jobs. Exp. Neurol. 192, 7-10.
3. Becher B., Prat A. and Antel J. P. (2000) Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29, 293-304.
4. Bond M., Murphy G., Bennett M. R., Newby A. C. and Baker A. H. (2002) Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J. Biol. Chem. 277, 13 787-13 795.
5. Broderick C., Hoek R. M., Forrester J. V., Liversidge J., Sedgwick J. D. and Dick A. D. (2002) Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am. J. Pathol. 161, 1669-1677.
6. Bugno M., Witek B., Bereta J., Bereta M., Edwards D. R. and Kordula T. (1999) Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett. 448, 9-14.
7. Campbell I. L. (2002) Cytokine-mediated inflammation and other actions in the central nervous system, in Ernst Schering Res. Found. Workshop 39, 61-83.
8. Campbell I. L., Abraham C. R., Masliah E., Kemper P., Inglis J. D., Oldstone M. B. and Mucke L. (1993) Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl Acad. Sci. USA 90, 10 061-10 065.
9. Carr D. J., Veress L. A., Noisakran S. and Campbell I. L. (1998) Astrocyte-targeted expression of IFN-alpha1 protects mice from acute ocular herpes simplex virus type 1 infection. J. Immunol. 161, 4859-4865.
10. Chauvet N., Palin K., Verrier D., Poole S., Dantzer R. and Lestage J. (2001) Rat microglial cells secrete predominantly the precursor of interleukin-1beta in response to lipopolysaccharide. Eur. J. Neurosci. 14, 609-617.
11. Chesler L., Golde D. W., Bersch N. and Johnson M. D. (1995) Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86, 4506-4515.
12. Clements J. M., Cossins J. A., Wells G. M. et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74, 85-94.
13. Crocker S. J. and Campbell I. L. (2005) Tissue inhibitors of matrix metalloproteinases, inflammation, and the central nervous system, in Matrix Metalloproteinases in the Central Nervous System (Contant K. and Gottschall P. E., eds). Imperial College Press, London, UK, pp. 311-322.
14. Crocker S. J., Pagenstecher A. and Campbell I. L. (2004) The TIMPs tango with MMPs and more in the central nervous system. J. Neurosci. Res. 75, 1-11.
15. Cunningham L. A., Wetzel M. and Rosenberg G. A. (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50, 329-339.
16. D'Souza C. A., Mak B. and Moscarello M. A. (2002) The up-regulation of stromelysin-1 (MMP-3) in a spontaneously demyelinating transgenic mouse precedes onset of disease. J. Biol. Chem. 277, 13589-13596.
17. Dubois B., Masure S., Hurtenbach U. et al. (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104, 1507-1515.
18. Esparza J., Kruse M., Lee J., Michaud M. and Madri J. A. (2004) MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J. 18, 1682-1691.
19. Ford A. L., Foulcher E., Lemckert F. A. and Sedgwick J. D. (1996) Microglia induce CD4 T lymphocyte final effector function and death. J. Exp. Med. 184, 1737-1745.
20. Gasson J. C., Golde D. W., Kaufman S. E. et al. (1985) Molecular characterization and expression of the gene encoding human erythroid- potentiating activity. Nature 315, 768-771.
21. Gijbels K., Galardy R. E. and Steinman L. (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94, 2177-2182.
22. Gottschall P. E. and Yu X. (1995) Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 64, 1513-1520.
23. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E. and Iwata K. (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32.
24. Hoek R. M., Ruuls S. R., Murphy C. A. et al. (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768-1771.
25. Jack C. S., Arbour N., Manusow J., Montgrain V., Blain M., McCrea E., Shapiro A. and Antel J. P. (2005) TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 175, 4320-4330.
26. Keyszer G., Lambiri I., Nagel R., Keysser C., Keysser M., Gromnica-Ihle E., Franz J., Burmester G. R. and Jung K. (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol. 26, 251-258.
27. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F. and Joh T. H. (2005) Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25, 3701-3711.
28. La Fleur M., Underwood J. L., Rappolee D. A. and Werb Z. (1996) Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J. Exp. Med. 184, 2311-2326.
29. Larsen P. H., Wells J. E., Stallcup W. B., Opdenakker G. and Yong V. W. (2003) Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J. Neurosci. 23, 11 127-11 135.
30. Leppert D., Hughes P., Huber S., Erne B., Grygar C., Said G., Miller K. M., Steck A. J., Probst A. and Fuhr P. (1999) Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology 53, 62-70.
31. Leveque T., Le Pavec G., Boutet A., Tardieu M., Dormont D. and Gras G. (2004) Differential regulation of gelatinase A and B and TIMP-1 and -2 by TNFalpha and HIV virions in astrocytes. Microbes Infect. 6, 157-163.
32. Lorenzl S., De Pasquale G., Segal A. Z. and Beal M. F. (2003a) Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 34, e37-38.
33. Lorenzl S., Albers D. S., LeWitt P. A., Chirichigno J. W., Hilgenberg S. L., Cudkowicz M. E. and Beal M. F. (2003b) Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 207, 71-76.
34. Maeda A. and Sobel R. A. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55, 300-309.
35. Mandel M., Gurevich M., Pauzner R., Kaminski N. and Achiron A. (2004) Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin. Exp. Immunol. 138, 164-170.
36. Milner R. and Campbell I. L. (2002) Cytokines regulate microglial adhesion to laminin and astrocyte extracellular matrix via protein kinase C-dependent activation of the alpha6beta1 integrin. J. Neurosci. 22, 1562-1572.
37. Milner R. and Campbell I. L. (2003) The extracellular matrix and cytokines regulate microglial integrin expression and activation. J. Immunol. 170, 3850-3858.
38. Minagar A., Shapshak P., Fujimura R., Ownby R., Heyes M. and Eisdorfer C. (2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202, 13-23.
39. Muir E. M., Adcock K. H., Morgenstern D. A., Clayton R., von Stillfried N., Rhodes K., Ellis C., Fawcett J. W. and Rogers J. H. (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res. Mol. Brain Res. 100, 103-117.
40. Mun-Bryce S. and Rosenberg G. A. (1998) Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am. J. Physiol. 274, R1203-R1211.
41. Noble L. J., Donovan F., Igarashi T., Goussev S. and Werb Z. (2002) Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 22, 7526-7535.
42. Nygardas P. T. and Hinkkanen A. E. (2002) Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 128, 245-254.
43. Nygardas P. T., Gronberg S. A., Heikkila J., Joronen K., Sorsa T. and Hinkkanen A. E. (2004) Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2. Scand. J. Immunol. 60, 372-381.
44. Pagenstecher A., Stalder A. K. and Campbell I. L. (1997) RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J. Immunol. Meth. 206, 1-9.
45. Pagenstecher A., Stalder A. K., Kincaid C. L., Shapiro S. D. and Campbell I. L. (1998) Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152, 729-741.
46. Pagenstecher A., Stalder A. K., Kincaid C. L., Volk B. and Campbell I. L. (2000a) Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am. J. Pathol. 157, 197-210.
47. Pagenstecher A., Lassmann S., Carson M. J., Kincaid C. L., Stalder A. K. and Campbell I. L. (2000b) Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J. Immunol. 164, 4481-4492.
48. Penkowa M., Camats J., Hadberg H., Quintana A., Rojas S., Giralt M., Molinero A., Campbell I. L. and Hidalgo J. (2003) Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J. Neurosci. Res. 73, 481-496.
49. Pinteaux E., Parker L. C., Rothwell N. J. and Luheshi G. N. (2002) Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J. Neurochem. 83, 754-763.
50. Qin H., Moellinger J. D., Wells A., Windsor L. J., Sun Y. and Benveniste E. N. (1998) Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. J. Immunol. 161, 6664-6673.
51. Raivich G. and Banati R. (2004) Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res. Brain Res. Rev. 46, 261-281.
52. Rivera S., Ogier C., Jourquin J., Timsit S., Szklarczyk A. W., Miller K., Gearing A. J., Kaczmarek L. and Khrestchatisky M. (2002) Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur. J. Neurosci. 15, 19-32.
53. Rosenberg G. A. (2002) Matrix metalloproteinases in neuroinflammation. Glia 39, 279-291.
54. Soilu-Hanninen M., Eralinna J. P., Hukkanen V., Roytta M., Salmi A. A. and Salonen R. (1994) Semliki Forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage. J. Virol. 68, 6291-6298.
55. Stephens E. B., Singh D. K., Kohler M. E., Jackson M., Pacyniak E. and Berman N. E. (2003) The primary phase of infection by pathogenic simian-human immunodeficiency virus results in disruption of the blood-brain barrier. AIDS Res. Hum. Retroviruses 19, 837-846.
56. Suryadevara R., Holter S., Borgmann K., Persidsky R., Labenz-Zink C., Persidsky Y., Gendelman H. E., Wu L. and Ghorpade A. (2003) Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia 44, 47-56.
57. Tan H. K., Heywood D., Ralph G. S., Bienemann A., Baker A. H. and Uney J. B. (2003) Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol. Cell Neurosci. 22, 98-106.
58. Teesalu T., Hinkkanen A. E. and Vaheri A. (2001) Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am. J. Pathol. 159, 2227-2237.
59. Trajkovic V., Vuckovic O., Stosic-Grujicic S. et al. (2004) Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. Glia 47, 168-179.
60. Vos C. M. P., Geurts J. J. G., Montagne L., van Haastert E. S., Bo L., van der Valk P., Barkhof F. and de Vries H. E. (2005) Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis. 20, 953-960.
61. Waubant E., Goodkin D. E., Gee L., Bacchetti P., Sloan R., Stewart T., Andersson P. B., Stabler G. and Miller K. (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53, 1397-1401.
62. Waubant E., Gee L., Miller K., Stabler G. and Goodkin D. (2001) IFN-betala may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 21, 181-185.
63. Waubant E., Goodkin D., Bostrom A., Bacchetti P., Hietpas J., Lindberg R. and Leppert D. (2003) IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60, 52-57.
64. Yong V. W., Krekoski C. A., Forsyth P. A., Bell R. and Edwards D. R. (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 75-80.